In vitro activity for RECARBRIO™ (imipenem, cilastatin, and relebactam)
Learn about:
In the Study for Monitoring Antimicrobial Resistance Trends (SMART),
RECARBRIO demonstrated potent in vitro activity1
The Study for Monitoring Antimicrobial Resistance Trends (SMART) represents the commitment of Merck to monitor the in vitro susceptibility of clinical bacterial Gram-negative isolates to antimicrobials in intra-abdominal (since 2002), urinary tract (since 2009), respiratory (since 2015), and bloodstream infections (since 2019). SMART was initiated in 2002 and is a global study.
The International Health Management Association conducts the SMART global antimicrobial surveillance program on behalf of Merck to report the in vitro activity of ceftolozane/tazobactam, imipenem/relebactam, and comparator agents against contemporary clinical isolates collected from medical centers located in various geographical regions (ie, Europe, Asia/South Pacific, Middle East/Africa, Latin America, Canada, and the United States).
The limitations of SMART surveillance include the small number of sites per country, changes over time in the sites participating in SMART, and the relatively small number of isolates tested each year (n=250 per site). In addition, the lack of clinical information does not allow for confirmation of isolates as being “community acquired” vs “hospital acquired.”
Enterobacteriaceae: C. freundii, E. cloacae, E. coli, K. aerogens, K. oxytoca, K. pneumoniae, S. marcescens
Antimicrobial susceptibility of Enterobacteriaceae isolates in US surveillance data (2021-2022)a
![Susceptibility Rates for RECARBRIO™ (imipenem, cilastatin, and relebactam) vs. Piperacillin/tazobactam](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_2_hor_a1v3_LO_638c7b.png)
![Susceptibility Rates for RECARBRIO™ (imipenem, cilastatin, and relebactam) vs. Piperacillin/tazobactam](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_2_hor_a1v3_LO_638c7b.png)
a Isolates collected from both ICU and non-ICU settings in the United States from 2021–2022 for the SMART surveillance program.
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.
- The clinical significance of in vitro data is unknown.
Antimicrobial susceptibility of K. Pneumoniae isolates in US surveillance data (2018-2022)a
![](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_3_hor_a1v3_LO_7dcd60.png)
![](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_2_hor_a1v3_LO_638c7b.png)
a Isolates collected from both ICU and non-ICU settings in the United States from 2018–2022 for the SMART surveillance program.
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.
- The clinical significance of in vitro data is unknown.
Antimicrobial susceptibility of ESBL+ Enterobacteriaceae isolates in US surveillance data (2021-2022)a
![](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_4_hor_a1v3_LO_f615a6.png)
![](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_2_hor_a1v3_LO_638c7b.png)
aIsolates collected from both ICU and non-ICU settings in the United States from 2021–2022 for the SMART surveillance program.
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.
- The clinical significance of in vitro data is unknown.
Antimicrobial susceptibility of P. aeruginosa isolates in US surveillance data (2021-2022)a
![](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_1_hor_a1v3_LO_01bbb0.png)
![](https://www.merckconnect.com/recarbrio/wp-content/uploads/sites/134/2024/05/CAT_REC_In-Vitro_2_hor_a1v3_LO_638c7b.png)
aIsolates collected from both ICU and non-ICU settings in the United States from 2021–2022 for the SMART surveillance program.
- Culture and susceptibility information and local epidemiology should be considered in modifying antibacterial therapy.
- The clinical significance of in vitro data is unknown.
NS, nonsusceptible.
Reference
- Data available on request from Merck & Co., Inc., Professional Services DAP, WP1-27, PO Box 4, West Point, PA 19846-0004. Please specify information package US-TIX-00848.